During therapy with selective BRAF inhibitors, panniculitis with arthralgia represents a new adverse effect that can require dose reduction.
In case of this adverse effect, treatment with nonsteroidal anti-inflammatory drugs, such as etoricoxib, should be initiated early to keep patients on treatment and to avoid drug discontinuation and tumor progression.
2012-03-20
Eng.
Archives of dermatology
Department of Dermatology, University Hospital Essen, Essen, Germany.
Arch Dermatol. 2012 Mar;148(3):357-61
© Galenicom 1999-2013